Close

AbbVie (ABBV) Announces DALVANCE Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. LRCX
4. IBM
5. HCP
6. SPY
7. BSX
8. PI
9. NOW
10. ORCL


Go back to AbbVie (ABBV) Announces DALVANCE Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients
AbbVie (NYSE: ABBV) Delayed: 166.32 -1.48 (0.88%)
Previous Close $167.80    52 Week High $68.12 
Open $167.66    52 Week Low $50.71 
Day High $169.29    P/E 36.08 
Day Low $165.96    EPS $4.61 
Volume 1,067,762